AEB and EBC Channels Now Exclusively Broadcast via Ethiosat at 57 degrees East
24.2.2021 10:50:00 EET | Business Wire | Press release
SES, the leader in global content connectivity solutions, announced today that the Ethiosat platform is now broadcasting all channels of the Association of Ethiopian Broadcasters (AEB) and the Ethiopian Broadcasting Corporation (EBC) exclusively, including many of Ethiopia’s most popular channels such as EBS, ETV News and FANA TV. The variety of lifestyle, news, sport and educational channels – more than 90 channels, out of which 21 are in high definition (HD) – from 57 degrees East, offers unmatched quality and convenience previously not experienced by Ethiopians.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223006278/en/
AEB and EBC Channels Now Exclusively Broadcast via Ethiosat at 57 degrees East (Photo: Business Wire)
In December 2020, the Ethiopian Government announced that all satellite TV channels should be moved to SES’s NSS-12 satellite so that Ethiosat can meet the local TV audiences’ desire for local and international news and entertainment channels while fuelling growth in the Ethiopian media sector.
Since then, the AEB and the EBC have had their members migrate their TV channels and broadcast them from one orbital position rather than have their viewers navigate through a multitude of foreign channels.
To support this migration, SES, through its established Elevate Installer Training programme, and supported by local partners Ethiopian Broadcasting Authority (EBA) and Ethiopian Science and Space Institution (ESSTI), has carried out daily training sessions. As a result, there are now 20,000 certified installers from all regions across Ethiopia who are equipped to help Ethiopian viewers repoint their dishes and continue to watch their favourite local channels without any disruption.
“Repointing dishes for millions of TV households across Ethiopia is not an easy feat, and it’s only possible when we have committed partners such as SES. It has taken us slightly less than two months to get our members’ channels moved to Ethiosat via SES’s satellite, and we are pleased with the progress of repointing the antennas so far,” said Amman Fissehazion, Chairman of AEB.
“We can proudly say that Ethiopians now have their own dedicated TV platform hosting exclusively all Ethiopian satellite TV channels,” said Dr Getachew Dinku Godana, Director General of EBA. “In addition to the high-quality content that this platform is offering, the strategic collaboration behind it has contributed to the creation of jobs and a sense of unity among the Ethiopian population.”
“Our commitment to our local partners in Ethiopia has never been stronger. In an incredibly short time frame, together with our local partners, we have managed to train 20,000 installers and have all AEB and EBC channels now broadcast exclusively from Ethiosat,” said Steve Collar, CEO at SES. “However, our work doesn’t stop here. Together with our local team based in Addis Ababa, we will continue to work with our local partners to repoint dishes across the country, while making sure that Ethiosat continues to host the most attractive TV offering comprising local and international channels.”
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.
About Ethiosat
Ethiosat is Ethiopia’s first dedicated TV platform to host the most popular local channels. Ethiosat’s tagline “Colour Your World” is inspired by the colourfulness of Ethiopian culture and tradition. The logo is a representation of the fact that a dedicated platform has been created for Ethiopia via satellite. You can follow Ethiosat on social media: Facebook (@ethiosatTV), Instagram(@ethiosat) or Telegram (@EthiosaTV).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223006278/en/
Contact information
Suzanne Ong
External Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom